Anzeige
Mehr »
Login
Mittwoch, 06.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus“ in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
81 Leser
Artikel bewerten:
(0)

Loftware, Inc.: Loftware and Signant Health Announce Availability of Integrated Clinical Supplies Labeling Solution

Automates to improve speed, enable compliance, and support scalability

PORTSMOUTH, N.H., Oct. 31, 2024 /PRNewswire/ -- Loftware, the global leader in Enterprise Labeling and Artwork Management solutions, and Signant Health, the leader in evidence generation for modern clinical trials, today announced the general availability of their integrated solution. This new offering connects the Loftware Cloud Clinical Trials platform with Signant Health's GxP Inventory Clinical Supplies Management application.

New Loftware logo

The new integration supports automation in three key areas. Firstly, it allows clinical trial master data held in GxP Inventory to be transferred into the Loftware Cloud Clinical Trials platform, removing the risk of errors from manual entry processes. Secondly, print requests can be created and approved directly within the GxP Inventory application, thereby improving efficiency and usability. Finally, print status updates are then sent back from Loftware Cloud Clinical Trials to GxP Inventory automatically, ensuring that forward processes in manufacturing can be initiated promptly.

"We've seen explosive growth in direct-to-site and direct-to-patient clinical trial supply models, as well as requests for just-in-time packaging to accommodate advanced medicinal products," said Oliver Cunningham, vice president of supplies management solutions at Signant. "Loftware's industry-leading labeling capabilities, integrated with our SmartSignals Supplies solution and user workflows, offers customers the agility needed to maximize performance and compliance of their clinical supplies."

Pharmaceutical companies must scale their clinical supplies management capabilities to address the growing volume and complexity of global clinical trials. Reliance on legacy systems or manual processes introduces the risk of delays, errors, and potential non-compliance with regulatory standards. The close integration between Loftware Cloud Clinical Trials and Signant's GxP Inventory Clinical Supplies Management application delivers the automation necessary to enhance the efficiency, accuracy, and speed of the end-to-end clinical supplies and labeling process.

Simon Jones, Loftware VP Product Management, Life Sciences, added: "The integration between Loftware Cloud Clinical Trials and Signant 's GxP Inventory marks a significant step forward in automating critical aspects of clinical supply chain management. By streamlining data transfer and automating labeling processes, pharmaceutical companies can now accelerate trial timelines, enhance compliance, and reduce risks, all while maintaining the highest levels of accuracy and efficiency."

Loftware and Signant Health anticipate this as a first release of an evolving product integration intended to support emerging industry best practices. Find out more here.

About Loftware

No matter what the challenge - digital transformation, time to market, or brand authenticity - Loftware can help you make your mark. We understand how global supply chains work and know that each item you produce, and ship is an expression of your company's brand. We can help you improve accuracy, traceability, and compliance while improving the quality, speed, and efficiency of your labeling. Our end-to-end cloud-based labeling platform helps businesses of all sizes manage labeling across their operations and supply chain and our solutions are used to print over 51 billion labels every year. Loftware also fosters supply chain agility and supports evolving customer and regulatory requirements, helping companies save over $200 million in fines annually. And with over 500 industry experts and 1,000 global partners, Loftware maintains a global presence with offices in the US, UK, Germany, Slovenia, China, and Singapore making us a trusted partner for companies in automotive, chemicals, clinical trials, consumer products, electronics, food & beverage, manufacturing, medical device, pharmaceuticals, retail/apparel, and more.

About Signant Health

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes - including all Top 20 pharma - have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at?www.signanthealth.com

Media contacts:

Laura Hindley, Senior PR & Communications Manager, Loftware, lhindley@loftware.com
Heather Bilinski, Senior Director, Corporate Marketing, Signant Health, heather.bilinski@signanthealth.com

Logo - https://mma.prnewswire.com/media/1658239/Loftware_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/loftware-and-signant-health-announce-availability-of-integrated-clinical-supplies-labeling-solution-302292834.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.